分子影像在蒙药机制研究中初探:RGD显像验证森登-4抗类风湿性关节炎血管形成机制

Mongolian medicine plays an important role in the treatment of many chronic diseases and can delay the progress of the disease. However, there is no effective way to verify the treatment mechanism and effect.Molecular imaging can be used to verify the treatment mechanism and effect by labling different imaging agents.In this study, rheumatoid arthritis (RA) as the starting point, molecular targeted imaging was used to validatethe mechanism and efficacy of the Mongolian medicine treatment of RA.Synovial pannus formation is the most important pathological manifestation of RA, which can lead to severe joint deformity and loss of function, high morbidity and mortality. Conventional and biological agents treatment have many side effects for RA. Many prescription agents have been accumulated in the treatment of RA. Mongolian medicine accumulated many effective and less adverse effects prescription for RA. In this study, 99mTc-labeled arginine-glycine-aspartic acid (Arg-Gly-Asp, RGD) peptides, which is highly selective for integrin αvβ3 receptor with high expression on RA neovascular cells, were used to imaging in vivo (rats and patients) to verify mechanism and efficacy of Mongolian medicine(Senden-4 soup).Clinical treatment of rheumatoid arthritis and confirm with Histopathology，It will lay a theoretical foundation for clinical treatment of rheumatoid arthritis and establish the model for screening and evaluating the efficacy of Mongolian medicine.It provides a theoretical basis for clinical treatment of rheumatoid arthritis in Mongolian medicine and establishes an evaluation model for the efficacy screening and verification of Mongolian medicine in vivo.

蒙药在许多慢性疾病治疗中扮演重要角色，可延缓疾病的进程，但目前尚无有效的方法来验证其治疗机制和效果，分子影像可以通过标记不同的显像剂在活体验证其治疗机制和效果。本研究以类风湿关节炎(RA)为切入点，应用分子靶向显像在活体内验证蒙药治疗RA的机制和疗效。目前针对RA的常规及生物制剂治疗方法有诸多副作用，而蒙药在治疗RA方面积累了疗效确切且不良反应较少的方剂。滑膜血管翳形成是RA最重要的病理表现，可以导致患者出现严重的关节畸形及功能丧失，有较高致残率及死亡率。本研究利用99mTc标记的精氨酸-甘氨酸-天冬氨酸（RGD）的多肽，这个能与RA新生血管细胞表面高表达的整合素αvβ3受体高选择性和特异性结合的靶向受体显像剂在活体内（大鼠及患者）进行显像来验证蒙药（森登-4汤为代表）抗RA滑膜血管翳的机制并与组织病理相互印证，为蒙医临床治疗类风湿关节炎奠定理论基础并建立活体筛选和验证蒙药疗效的评估模式。

蒙药在许多慢性疾病治疗中扮演重要角色，可延缓疾病的进程，但目前尚无有效的方法来验证其治疗机制和效果，分子影像可以通过标记不同的显像剂在活体验证其治疗机制和效果。本研究以类风湿关节炎(RA)为切入点，应用分子靶向显像在活体内验证蒙药治疗RA的机制和疗效。目前针对RA的常规及生物制剂治疗方法有诸多副作用，而蒙药在治疗RA方面积累了疗效确切且不良反应较少的方剂。滑膜血管翳形成是RA最重要的病理表现，可以导致患者出现严重的关节畸形及功能丧失，有较高致残率及死亡率。本研究利用99mTc标记的精氨酸-甘氨酸-天冬氨酸（RGD）的多肽，这个能与RA新生血管细胞表面高表达的整合素αvβ3受体高选择性和特异性结合的靶向受体显像剂在活体内（大鼠及患者）进行显像来验证蒙药（森登-4汤为代表）抗RA滑膜血管翳的机制并与组织病理相互印证，为蒙医临床治疗类风湿关节炎奠定理论基础并建立活体筛选和验证蒙药疗效的评估模式。